Max Healthcare Institute Limited (543220) Earnings Call Transcripts

Max Healthcare Institute Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Max Healthcare Institute Limited reported a revenue increase of 10% year-on-year to INR 2,664 crores, with operating EBITDA growing by 8% to INR 682 crores. The company maintained its strong operational performance, achieving its 22nd consecutive quarter of year-on-year growth. Management provided guidance for FY '27, focusing on scaling recently commissioned capacities and integrating Kalinga Hospital, while also indicating a continued commitment to capital discipline. The acquisition of Kalinga Hospital and ongoing expansion projects signal potential for future growth, although the discontinuation of high-value chemotherapy drugs has impacted oncology revenue significantly.

Reported metrics

Guidance from management

Management indicated a focus on scaling recently commissioned capacities and integrating Kalinga Hospital into the network. They expect to see significant operating leverage as these capacities ramp up over the next quarters.

What management said

So I think in fiscal '28, we will be looking at breaking even within the year. I mean it's a greenfield, as you're aware. Having said that, our experience with the Dwaraka Greenfield, again, we operationalized it. We guided to a 1-year breakeven. We actually broke even it in 6 months. We had an operating loss, consolidated loss in the first 6 months of I think about INR 35 crores, INR 40 crores. But by the end of the...

So I think there are 2 things. You have onco drug because this is day care, right? You have onco drugs margins, which are sort of -- which were coming out a little perverse to us. So discontinuation of these high-value drugs not only impacts our top line, but also impacts your related OB days, occupied bed days which are related to it because some of the patients which are coming for this thing are also admitted at n...

What analysts pressed on

Analysts expressed concerns regarding the impact of the chemotherapy drug discontinuation on revenue and occupancy rates. There were also questions about the timeline for the operationalization of new beds and the potential for future delays in expansion projects.

Main topics on the call

• Revenue Growth — Max Healthcare's revenue for Q4 FY '26 reached INR 2,664 crores, a 10% increase year-on-year. Management noted, "the network delivered its 22nd consecutive quarter of year-on-year growth," indicating strong operational m...
• Acquisition of Kalinga Hospital — The acquisition of a controlling stake in Kalinga Hospital Limited marks Max Healthcare's entry into Eastern India, providing a platform for future expansion. Management stated, "The acquisition marks our entry into East...
• Impact of Chemotherapy Drug Discontinuation — The discontinuation of select high-value chemotherapy drugs led to a 21% drop in oncology revenue share, from 26% in Q4 FY '25. Management acknowledged that this had a significant impact, stating, "the share of oncology ...
• Expansion Plans — Management outlined plans for significant capacity expansion, including a 700-bed greenfield hospital in Lucknow and additional beds across various facilities. They emphasized, "We expect to add another 10% capacity once...

Read the full Max Healthcare Institute Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 18 Max Healthcare Institute Limited earnings call transcripts on record, spanning May 26, 2022 to August 14, 2026. Based on this history, Max Healthcare Institute Limited reports quarterly. The most recent call on file is dated August 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

543220

Exchange

BSE

Country

IN

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

18

First call

May 26, 2022

Most recent

August 14, 2026

Reporting cadence

quarterly